Johnson & Johnson acquired Intra-Cellular Therapies and is seeking FDA approval for related drugs.
5 reports, 5 independent
Updated Nov 6
Gone quiet
Reached 3 outlets in its first 24 hours
- Reports
- 5
- Developments
- 3
- Repetition
- 40%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Johnson & Johnson acquired Intra-Cellular Therapies and is seeking FDA approval for related drugs.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.FDA granted accelerated approval for a J&J drug.1 source
J&J acquired Intra-Cellular Therapies and is pursuing FDA approval for the acquired therapies.1 source
J&J seeks FDA approval for new immune drug; FDA rejects melanoma drug application.1 source
Keep exploring
The entities involved
- FDA
-
Johnson & Johnson
U.S multinational medical devices, pharmaceutical and consumer packaged goods manufacturer
Related events
Coverage
Newest first; wire copies grouped- prnewswire.com
- yahoo.com
- ZacksJ&J Gears Up for Some Key New Drug Approvals and Launches Johnson & Johnson JNJ, like any other large drugmaker, boasts a robust R&D pipeline of drugs, with its key focus areas being immunology, onco
- BioPharma DiveReplimune drug rejected by FDA; Omega raises $647M biotech fund This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive n
- ACCESS NewswireProtagonist Announces Submission of NDA for First Icotrokinra U.S. FDA Approval Aiming to Revolutionize Treatment Paradigm for Adults and Adolescents with Plaque Psoriasis Icotrokinra is a first-in-c